Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 8/20 | 0.37 |
| ▸ | EGFR | P00533 | 7/20 | 0.35 |
| ▸ | SRC | P12931 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | TNF | P01375 | 3/20 | 0.34 |
| ▸ | LITAF | Q99732 | 3/20 | 0.34 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.32 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.31 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24691792 | 0.95 | KRAS (0.41) | KRAS | |
| SCHEMBL24692579 | 0.89 | KRAS (0.44) | KRAS | |
| SCHEMBL24692595 | 0.87 | KRAS (0.42) | KRAS | |
| SCHEMBL23136633 | 0.86 | KRAS (0.38) | KRAS | |
| SCHEMBL29907484 | 0.85 | KRAS (0.47) | KRAS | |
| SCHEMBL24692782 | 0.85 | KRAS (0.51) | KRAS | |
| SCHEMBL23137565 | 0.85 | KRAS (0.51) | KRAS | |
| SCHEMBL25830209 | 0.84 | KRAS (0.41) | KRAS | |
| SCHEMBL25830225 | 0.83 | KRAS (0.36) | KRASNTRK1MAP4K1 | |
| SCHEMBL25829767 | 0.83 | KRAS (0.43) | KRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227472-A1 | FUSED PYRIDONE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD (CN) | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227472-A1 | FUSED PYRIDONE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | KRAS, NRAS, WEE1 | KRAS 1/4885EGFR 269/4885SRC 614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.